Fig. 1

Synthesis of CEP-37440




Fig. 2

XRPD Pattern of the CEP-37440 tribenzenesulfonate salt




Fig. 3

XRPD Pattern of the CEP-37440 trihydrochloride dihydrate salt




Fig. 4

Anti-Tumor Efficacy of CEP-37440 in Sup-M2 ALCL Tumor Xenografts in Mice with Oral Dosing




Fig. 5

Body Weights of Mice Bearing Sup-M2 ALCL Tumor Xenografts with CEP-37440 Oral Dosing




Fig. 6

Plasma and Tumor Levels of CEP-37440 in Mice Bearing Sup-M2 ALCL Tumor Xenografts with Oral Dosing




Fig. 7

Anti-Tumor Efficacy of CEP-37440 in Karpas-299 Tumor Xenografts in Mouse with Oral Dosing




Fig. 8

Body Weights of Mice Bearing Karpas-299 Tumor Xenografts with CEP-37440 Oral Dosing




Fig. 9

Plasma and Tumor Levels of CEP-37440 in Mice Bearing Karpas-299 Tumor Xenografts with Oral Dosing




Fig. 10

Anti-Tumor Efficacy of CEP-37440 in NCI-H2228 NSCL Tumor Xenografts in Mice with Oral Dosing




Fig. 11

Anti-Tumor Efficacy of CEP-37440 in NCI-H3122 NSCL Tumor Xenografts in Mice with Oral Dosing




Fig. 12

Plasma and Tumor Levels of CEP-37440 in Mice Bearing NCI-H2228 NSCL Tumor Xenografts with Oral Dosing




Fig. 13

Plasma and Tumor Levels of CEP-37440 in Mice Bearing NCI-H3122 NSCL Tumor Xenografts with Oral Dosing




Fig. 14

Body Weights of Mice Bearing NCI-H2228 NSCL Tumor Xenografts with CEP-37440 Oral Dosing




Fig. 15

Body Weights of Mice Bearing NCI-H3122 NSCL Tumor Xenografts with CEP-37440 Oral Dosing





Fig. 16

Anti-Tumor Efficacy and Long Term Tumor Regressions by CEP-37440 in NCI-H2228 NSCL Tumor Xenografts in Mouse




Treatment initiated on day 1

\# On day 12, the two CEP-37440-treated groups combined and then continued to be dosed @ 55 mg/kg, qd

* Dosing stop on day 40

Fig. 17

Body Weights of Mice Bearing NCI-H2228 NSCL Tumor Xenografts with CEP-37440 Oral Dosing



treatment initiated on day 1

\# On day 12, the two treated group combined and then continued to be dosed @ 55 mg/kg qd

* Dosing stop on day 40

Fig. 18

Anti-Tumor Efficacy of CEP-37440 and PF-562271 in Nude Mice Bearing PC-3 Prostate Tumor Xenografts with Constitutive FAK Activation




Fig. 19

Anti-tumor Efficacy of CEP-37440 and PF-562271 in Nude Mice Bearing HCC-827 Human NSCL Carcinoma Xenografts (EML4-ALK negative)




Fig. 20

Body Weights of Nude Mice Bearing HCC-827 Human NSCL Carcinoma Xenografts (EML4-ALK negative) with CEP-37440 or PF-562271 Oral Dosing




Fig 21

Tumor Pharmacodynamic Inhibition of FAK and Anti-tumor Efficacy of CEP-37440 and PF-562271 in SCID Mice Bearing Detroit 562 Human HNSCC Carcinoma Xenografts (EML4-ALK negative)

